NewsRoom Articles - Page 84 of 154 - PsychedelicNewsWire (PNW)

MondaySep 20, 2021 2:00 pm

Study Finds Way to Explain LSD’s Potency

LSD is among the most potent and longest-lasting psychedelic substances. Until recently, scientists hadn’t fully understood why LSD’s effects lingered for more than 12 hours. However, a study has found that how the drug fits into brain receptors can help explain the drug’s longevity. The study was published in “Cell.” The study’s senior co-author Bryan Roth stated that many individuals who ingested LSD weren’t aware of how long its effects would last. For their study, researchers from Roth’s laboratory captured crystallography images of an LSD molecule that was bound to the serotonin receptors in the brain. Crystallography images are images…

FridaySep 17, 2021 2:00 pm

Study Finds Ketamine Safe for Use in Managing Treatment-Resistant Depression

New research conducted by researchers from the Federal University of Bahia has found that ketamine and esketamine may be used safely as a treatment for depression. Ketamine is a synthetic compound used as an anesthesia drug while esketamine is an anesthetic that has been used to manage treatment-resistant depression. Ketamine is sometimes abused as a club drug and is popularly referred to as Special K and K in this scenario. Various studies suggest that low doses of ketamine offer rapid antidepressant effects, improving a patient’s mood within 24 hours. Esketamine has been shown to possess similar benefits. A version of…

FridaySep 17, 2021 9:00 am

Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concerns Tryp is preparing Phase 2a and Phase 2b clinical trials and expects to advance its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) platform in conjunction with research teams at the University of Florida and the University of Michigan The DEA recently recommended a significant increase in cannabis…

ThursdaySep 16, 2021 2:00 pm

Researchers Find That Encounters with ‘Higher Power’ May Improve Mental Health

Over the millennia, different individuals have admitted to experiencing deeply moving religious encounters, sometimes spontaneously and sometimes while under the influence of psychedelics, including ayahuasca or psilocybin. Researchers at Johns Hopkins Medicine recently conducted a survey involving individuals who had admitted to experiencing personal encounters with a higher power. The survey results indicated that more than half of the individuals who identified as atheists stopped identifying as such so after their experience, regardless of whether it was brought on while under the influence of a psychedelic or if it was spontaneous. Additionally, most of the respondents credited the lasting positive…

WednesdaySep 15, 2021 12:30 pm

Oregon Psilocybin Panel Joins Harvard to Study Psychedelic History

Researchers cleared by the Oregon Psilocybin Advisory Board will be working with Harvard Law School to study the culture and history of psychedelics. The aim of this new research project is to help inform legislative efforts in other states where psychedelics reform is being pursued. In an interview, Mason Marks, director of Harvard’s Psychedelics Policy Center, stated that Oregon was one of the few states exploring the regulation of psilocybin services, adding that the project would help inform decision making. Marks is also a member of Oregon’s Psilocybin Advisory Board. The panel, whose objective is to advise on the implementation…

TuesdaySep 14, 2021 12:35 pm

Michigan Senators Introduce Bill to Legalize Cultivation, Possession of Psychedelic Substances

Last week, senators in the state of Michigan introduced a piece of legislation that would legalize the possession, growing and delivery of various fungi- and plant-derived psychedelics, including mescaline and psilocybin. The bill, which was sponsored by Senators Adam Hollier and Jeff Arwin, would alter state statutes to exempt individuals from criminal penalties for such activities, as long as they weren’t receiving valuable consideration, cash as money for the entheogenic fungi and/or plants. This is because commercial sales and production of the psychedelics wouldn’t be legal under the initiative. However, the measure does clarify that individuals would be allowed to…

TuesdaySep 14, 2021 9:48 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments

Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression Administering drug to mice resulted in an approximately 10% increase in neuron size and density Cybin is focused on progressing psychedelic therapeutics As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers that a single dose of psilocybin counteracts symptoms of depression (https://ibn.fm/NCORl) — companies operating in the space, including Cybin (NEO: CYBN) (NYSE American: CYBN), are ideally positioned to see significant benefits and growth. “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin…

MondaySep 13, 2021 2:07 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders Tryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the University of Florida The company also understands the value of proper leadership and, so far in 2021, it has made strategic appointments to its board of directors Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)…

MondaySep 13, 2021 12:35 pm

Biden Administration Streamlines Registration Processes for Research on Schedule I Substances

Last week, the White House Office of National Drug Control Policy recommended that a modification be made to the federal drug scheduling system in an effort to simplify the process of conducting studies on schedule I substances, which include cannabis and psychedelics like psilocybin. In a letter to Congressional leaders, the ONDCP stated that it wanted to encourage research on the substances by streamlining the registration process for researchers to access Schedule I drugs. This move is part of an extensive initiative to develop a strategy to decrease the supply of illicit fentanyl while diminishing barriers to scientific research on…

FridaySep 10, 2021 2:00 pm

DEA to Increase Psilocybin, Cannabis Production for Research Purposes

The United States Drug Enforcement Administration (“DEA”) has proposed an increase in the manufacture of cannabis, cannabis extract, psilocin and psilocybin for clinical trial and research purposes. In its most recent notice, the DEA stated that its objective was to assist in the development of new federally approved therapies. The DEA stated that it believes in supporting the regulated research of controlled substances classified under Schedule I of the Controlled Substances Act. The increase in the aggregate production quota reflects this support and will help meet the requirements for research needed for the production of new therapeutic medications. This isn’t…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000